Overview

Proprietary Fibrosis Drug that has Breakthrough Potential.

iBio, in collaboration with Dr. Carol Feghali-Bostwick of the Medical University of South Carolina, is developing a proprietary therapeutic product for the treatment of systemic scleroderma with potential application to idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases.

Phase completed
not started
not started
not started
not started
not started
Preclinical Phase 1 Phase 2a Phase 2b Phase 3 Market
Preclinical Data for IBIO-CFB03 Indicates Ability to Stop or Even Reverse Fibrosis

Data published in 2012 by Dr. Feghali-Bostwick demonstrate that specific endostatin-derived peptides are useful for both inhibition and reversal of fibrosis in preclinical mouse models of fibrosis, as well as in human skin.

iBio has produced the active pharmaceutical ingredient using its patented iBio Technology and has made the clinical development of this promising product a key priority.

Market Need

What is Systemic Scleroderma?

Systemic Scleroderma is a disorder that affects connective tissue of skin and internal organs as well as the walls of blood vessels. Early diagnosis and individualized therapy can be helpful, but treatment of systemic scleroderma is limited to symptom management. No currently-approved drug has been proven to arrest the underlying process or processes that drive progression of the disease.

Key Figures
123,000 - 245,000 Prevalence of Systemic Scleroderma in US & EU
European Respiratory Review, 2012
What is Systemic Scleroderma?
What is Idiopathic Pulmonary Fibrosis (IPF)?

Idiopathic pulmonary fibrosis is a life-shortening lung disease with a rapidly progressing negative impact on quality of life leading to death within an average of three to five years after diagnosis

Key Figures
44-88KPrevalence of IPF in US
~188KPrevalence of IPF in EU
European Rrespiratory Review, 2012
What is Idiopathic Pulmonary Fibrosis (IPF)?